Medsky Topics
bit.ly
GLP-1 costs help push Dallas health plan over budget
Dallas expected to save $12 million on employee healthcare this year, but rising GLP-1 drug use and high-cost claims now have the plan projected $17 million over budget.
A Medsky Topics feed composed of posts covering recent news related to GLP-1 Agonists such as Semaglutide (Ozempic, Wegovy, Rybelsus), Liraglutide (Victoza), and Tirzepatide (Zepbound, Mounjaro) Powered by @medsky.network
Feed on BlueskyFeeds Stats
- 💙 Liked by 15users
- 📅 Updated 3 months ago
- ⚙️ Provider graze.social
GLP-1 Agonists Likes over time
Like count prediction
The feed GLP-1 Agonists has not gained any likes in the last month.Feed Preview for GLP-1 Agonists
🚨 Ozempic is not just a weight loss drug. Cardiologists already knew it. Now the data proves it. I am a cardiologist. And SELECT trial (semaglutide) changed everything I tell my patients. 17,604 people. No diabetes. All overweight or obese with existing heart disease. Half got semaglutide.
0
0
0
How Americans live—and eat—is being completely transformed by GLP-1 medications. Lior Lev Sercarz, a chef and spice master, has become acutely aware of the shift and is bringing flavor back.
🔗: www.wsj.com/arts-culture...
1
0
9
Dramatic weight loss from GLP-1 medications can lead to changes beyond the scale, including loose, sagging skin. ASPS Member Surgeons Drs. Michael Omidi and Kristy Hamilton weigh in on the effects of rapid weight loss and ways to address excess skin. fxn.ws/454Jbeb
0
0
0
New - Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2 randomised controlled trial
www.thelancet.com/journal….
#LiverSky #MedSky
www.thelancet.com
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-b...
In participants with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, the combination of zalfermin 30 mg plus semaglutide 2·4 mg did not significantly increase the...
0
1
1
This AJR Expert Panel Narrative Review proposes updated preparation strategies for oncologic [18F]FDG PET in patients with diabetes, addressing the impact of new glucose-lowering medications and insulin delivery technologies on image quality. www.ajronline.org/doi/10.….
www.ajronline.org
Advances in Diabetes Medications and Patient Preparation for Oncologic FDG PET: AJR Expert Panel Narrative Review | AJR
Preparation of patients with diabetes for oncologic [18F]FDG PET remains variable across institutions despite increasing diabetes prevalence and expanding use of emerging glucose-lowering medications and diabetes technologies. This AJR Expert Narrative Review examines effects of hyperglycemia and insulin exposure on [18F]FDG biodistribution and proposes preparation strategies for oncologic [18F]FDG PET. As few studies have systematically examined optimal approaches to glycemic control before [18F]FDG PET, the article integrates available literature with consideration of existing society guidelines in forming consensus-driven clinical guidance. Standard pre-examination practices include fasting, hydration, and avoidance of rapid- or short-acting insulin use. However, guidelines differ in serum glucose thresholds for patient triage, timing of insulin adjustments, and insulin pump recommendations. Additionally, limited guidance is available on SGLT-2 inhibitors, incretin-based therapies (e.g., GLP-1 receptor agonists), and automated insulin delivery systems. The panel supports standardized facility-level protocols, continued use of insulin pumps in basal mode, and general avoidance of correctional insulin immediately before imaging. A management algorithm incorporating point-of-care glucose assessment on patient arrival, relatively permissive glucose level thresholds, and approaches to avoid same-day cancellations is presented. Prospective studies are needed to evaluate the effects of individual glucose-lowering medication classes on [18F]FDG biodistribution and image quality.
0
1
0
#Incretin-based therapies, particularly #GLP-1 receptor agonists and dual GLP-1 and #GIP receptor agonists, represent a paradigm shift in obesity management, with their weight-lowering and glucose-lowering effects now approaching metabolic–bariatric surgery www.thelancet.com/journal….
#obesity
www.thelancet.com
Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement
Incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1–GIP receptor agonists, have transformed obesity management, producing substantial weight loss and cardiometabolic benefits, w...
0
0
3
Published in @eclinicalmed.bsky.social
The effectiveness of glucagon-like peptide-1 receptor agonists (#GLP-1RAs) on #binge #eating in patients with #obesity: a systematic review and meta-analysis www.thelancet.com/journal….
#OpenAccess
#MedSky #EndoSky #GastroSky
www.thelancet.com
The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis
GLP-1RAs reduced binge eating-related behaviours and emotional eating and increased cognitive or dietary restraint, though whether restraint is pathological is unclear. Given heterogeneity and high ri...
0
1
2
GLP-1 medications can make it harder to eat enough protein. Discover high-protein breakfast ideas that are filling, nutritious and designed to support your goals.
bit.ly
Breakfast and protein for GLP-1 medication users: Here are the morning meals worth trying now
GLP-1 medications can make it harder to eat enough protein. Discover high-protein breakfast ideas that are filling, nutritious and designed to support your goals.
1
0
1
Variable weight-loss and cardiovascular benefits were seen with GLP-1 drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear. @lisheyu.bsky.social @drmariespreckley.bsky.social
www.medpagetoday.com/prim…
0
0
0
💉 GLP-1 pros/cons
To your health Wednesday, July 15 — Happy Wednesday! ⚽ Atlanta is hosting its final FIFA World Cup game today, when England and Argentina play at 3 p.m....
roughdraftatlanta.com/202…
roughdraftatlanta.com
💉 GLP-1 pros/cons
To your health Wednesday, July 15 — Happy Wednesday! ⚽ Atlanta is hosting its final FIFA World Cup game today, when England and Argentina play at 3 p.m. I’m going to miss watching everyone’s favorite Norwegian, Erling Haaland, on and off the pitch. But he chose a very on-brand American souvenir to commemorate his World Cup experience — a taxidermy raccoon holding a bottle of whiskey. 🩺 STAT Wellness recently merged with Sandy Springs-based physical therapy practice, Well Equipt. The newest STAT location will combine physical therapy with functional medicine services, IV therapies, and small group personal training.
0
0
0
Exposure to #GLP1RA is not associated with an increased risk for incident malignancy among patients with endogenous #CushingSyndrome.
www.endocrinologyadvisor.…
www.endocrinologyadvisor.com
GLP-1RAs Do Not Increase Malignancy Risk in Endogenous Cushing Syndrome
A nationwide cohort study examines the oncologic safety of GLP-1 receptor agonists in patients with endogenous Cushing syndrome.
0
0
0
I spent £540 a month on takeaways - now I saved £4k & shed 11st with Mounjaro
www.thesun.co.uk
I spent £540 a month on takeaways - now I saved £4k & shed 11st with Mounjaro
0
0
0
For readers interested in pharmacotherapies for obesity, such as GLP-1-based drugs, here's a comprehensive recent review
www.nature.com/articles/s41...
rdcu.be/ftUQ1
www.nature.com
The evolving landscape of obesity pharmacotherapy - Nature Reviews Drug Discovery
Incretin-based therapies are transforming the treatment of obesity and related comorbidities. This Review outlines the current landscape of obesity drug development, focusing on glucagon-like peptide ...
0
1
4
FDA new drug approvals in Q2 2026
www.nature.com/articles/d41...
Q2 2026 saw a rebound for novel FDA drug approvals with a total of 13, also with heavy commercial firepower thanks to products such as the first oral small-molecule GLP-1 receptor agonist
0
0
0
‘Please don’t lose another pound!’: Ozempic is upending the wedding dress industry
www.theguardian.com
‘Please don’t lose another pound!’: Ozempic is upending the wedding dress industry
The ubiquity of GLP-1s is wreaking new havoc on bridal designers who must scramble to accommodate rapid weight loss
4
5
21
Quite apart from the constant drum-banging by so many news websites against GLP-1s, surely hardly anyone is using Ozempic now? It's Mounjaro and Wegovy. Ozempic is off-label for weight loss. www.theguardian.com/lifea….
www.theguardian.com
‘Please don’t lose another pound!’: Ozempic is upending the wedding dress industry
The ubiquity of GLP-1s is wreaking new havoc on bridal designers who must scramble to accommodate rapid weight loss
3
0
6
Atlanta doctors discuss the pros and cons of taking a GLP-1 for weight management
Rough Draft Atlanta spoke to two area physicians on how GLP-1s work, why strength training and other lifestyle habits can…
roughdraftatlanta.com/202…
roughdraftatlanta.com
Atlanta doctors discuss the pros and cons of taking a GLP-1 for weight management
Rough Draft Atlanta spoke to two area physicians on how GLP-1s work, why strength training and other lifestyle habits can support successful results, and who should take these drugs – or avoid them altogether.
0
0
0
A new biotech startup tries to tackle obesity, but not in the way you might expect www.statnews.com/2026/07/…. via @statnews.com
www.statnews.com
A new biotech startup tries to tackle obesity, but not in the way you might expect
A new startup is making a bold move in the world of obesity drug development: It’s not working with the GLP-1 target that has taken the world by storm.
0
0
2
Adding a GLP-1 receptor agonist was not associated with a lower likelihood of discontinuing existing basal insulin therapy among veterans with type 2 diabetes compared with other glucose-lowering agents, a target emulation trial found.
www.medpagetoday.com/endo…
www.medpagetoday.com
Study Dampens Hope for GLP-1s as Insulin Off-Ramp in Type 2 Diabetes
No difference in insulin discontinuation rates seen among three glucose-lowering classes
0
2
1
Study flags need to monitor frailty risks with GLP-1 drugs for older adults reut.rs/4vxAeVH
reut.rs
Study flags need to monitor frailty risks with GLP-1 drugs for older adults
Potential signs of frailty in older adults taking Eli Lilly’s GLP-1 obesity drug Zepbound may signal relatively high risks for adverse outcomes, according to a large study that underscores concerns about how best to monitor seniors as U.S. Medicare expands access to GLP-1 therapies.
2
9
22